Capital Fund Management S.A. Buys New Shares in Takeda Pharmaceutical Co. $TAK

Key Points

• Capital Fund Management S.A. acquired a new stake in Takeda Pharmaceutical Co., purchasing 39,946 shares valued at approximately $594,000.
• Institutional investors collectively own 9.17% of Takeda's stock, with several hedge funds increasing their positions during the first quarter.
• Takeda's latest earnings report showed earnings of $0.52 per share, surpassing estimates, although revenue fell short of expectations at $7.45 billion.

Capital Fund Management S.A. acquired a new position in Takeda Pharmaceutical Co. (NYSE:TAK - Free Report) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 39,946 shares of the company's stock, valued at approximately $594,000.

Other hedge funds have also recently made changes to their positions in the company. FNY Investment Advisers LLC bought a new position in Takeda Pharmaceutical in the first quarter worth approximately $37,000. Farther Finance Advisors LLC boosted its stake in Takeda Pharmaceutical by 29.2% in the 1st quarter. Farther Finance Advisors LLC now owns 4,620 shares of the company's stock worth $69,000 after purchasing an additional 1,045 shares in the last quarter. Fifth Third Bancorp grew its holdings in shares of Takeda Pharmaceutical by 85.5% during the first quarter. Fifth Third Bancorp now owns 5,232 shares of the company's stock valued at $78,000 after buying an additional 2,411 shares during the last quarter. Point72 Hong Kong Ltd purchased a new stake in Takeda Pharmaceutical during the 4th quarter valued at about $94,000. Finally, GAMMA Investing LLC increased its holdings in Takeda Pharmaceutical by 22.6% in the 1st quarter. GAMMA Investing LLC now owns 7,042 shares of the company's stock worth $105,000 after buying an additional 1,296 shares during the period. 9.17% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Separately, Zacks Research lowered Takeda Pharmaceutical from a "hold" rating to a "strong sell" rating in a research note on Thursday, August 21st. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Takeda Pharmaceutical has an average rating of "Hold".

Takeda Pharmaceutical Trading Up 0.1%

Shares of NYSE TAK traded up $0.02 during mid-day trading on Monday, reaching $14.99. 1,746,970 shares of the company's stock were exchanged, compared to its average volume of 3,411,340. The company's 50-day moving average is $14.81 and its 200-day moving average is $14.76. The firm has a market capitalization of $47.68 billion, a price-to-earnings ratio of 49.95 and a beta of 0.22. Takeda Pharmaceutical Co. has a 52-week low of $12.80 and a 52-week high of $15.56. The company has a debt-to-equity ratio of 0.60, a quick ratio of 0.59 and a current ratio of 1.16.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last announced its earnings results on Wednesday, July 30th. The company reported $0.52 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.47 by $0.05. Takeda Pharmaceutical had a return on equity of 10.50% and a net margin of 3.20%.The company had revenue of $7.45 billion for the quarter, compared to analyst estimates of $7.96 billion. Takeda Pharmaceutical has set its FY 2025 guidance at 3.360-3.360 EPS. Analysts expect that Takeda Pharmaceutical Co. will post 1.64 EPS for the current fiscal year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.